Grants-in-aid

We advertise for applications for grants-in-aid at the start of each year (for funding to start in January the following year).

Grants-in-aid support research for 1 to 3 years. They're awarded based on each project's:

  • relevance to cancer,
  • excellence,
  • the value of the research, and
  • the researcher's capacity to successfully complete the research described in the application.

All applications go through a rigorous peer-review process. The state Cancer Councils work in partnership with the National Health and Medical Research Council, which provides us with assessments and rankings.

In 2015 Cancer Council Victoria spent $3.2 million on grants-in-aid. Current recipients are listed below.


Dr Jeffrey Babon, Dr Nadia Kershaw
Walter and Eliza Hall Institute of Medical Research
The role of SOCS1 in inflammatory disease and cancer (2014-16)

Dr Yuan Cao
The University of Melbourne (Peter MacCallum Cancer Centre)
Contribution of platelet factor 4 to inhibition of metastasis driven by bone morphogenetic protein 4 (2016-17) 

Dr Colin Clyne, Dr Ashwini Chand, Prof Evan Simpson
Hudson Institute of Medical Research
LRH-1: a novel driver of breast cancer proliferation (2015-17)

Dr Suzanne Cutts, A/Prof Paul Pigram, Prof Geoff Pietersz, Dr Carleen Cullinane
La Trobe University
Tumour-targeted nanoparticles as sensitisers for cancer chemotherapy (2013-16)

A/Prof Phillip Darcy, A/Prof Michael Kershaw
Peter MacCallum Cancer Centre
Enhancing activation and trafficking of T cells for cancer therapy (2015-17)

Dr Andrew Deans, Dr Alessandro Costa
St Vincent's Institute of Medical Research
Mammalian reverse gyrase: a new target in the chemosensitisation of tumour cells (2015-16)

Dr Walter (Doug) Fairlie, Dr Erinna Lee, Dr Daniel Gray
Walter and Eliza Hall Institute of Medical Research (Jan 2014-Jun 2015), La Trobe University (Jul 2015-Dec 2016)
Mechanisms of Bcl-2 pro-survival protein regulation in normal physiology, tumourigenesis and drug responsiveness (2014-16)

Prof Peter Fuller, Dr Ann Drummond, Dr Morag Young, Prof Christine Clarke
Hudson Institute of Medical Research
Non-classical mineralocorticoid receptor signalling in reproductive tissues (2015-17)

Dr Stephan Glaser
Walter and Eliza Hall Institute of Medical Research
Investigating the requirement of pro-survival Bcl-2 family proteins in leukaemia (2014-16)

A/Prof Simon Harrison, Prof Ross Hannan, A/Prof Andrew Wei
Peter MacCallum Cancer Centre
Novel approaches to treat refractory haematological malignancies (2015-17)

A/Prof Kieran Harvey
Peter MacCallum Cancer Centre
Upstream signalling in the Hippo tumour suppressor pathway (2014-16)

A/Prof Kieran Harvey, Dr Nicola Waddell, A/Prof Kaylene Simpson
Peter MacCallum Cancer Centre
Deciphering the role of the Hippo pathway in mesothelioma
Lyall Watts Mesothelioma Research Grant (Sept 2016 - Aug 2019)

Prof Ygal Haupt, Dr Shahneen Sandhu
The University of Melbourne
Restoration of tumour suppression in prostate cancer by targeting the ubiquitin proteasome system (2015-17)

Dr Nicole Haynes
The University of Melbourne (Peter MacCallum Cancer Centre)
Harnessing the immune system with epigenetic therapies to treat HER2+ breast cancer (2016-18)

Dr Duangporn Jamsai, Prof Moira O'Bryan
Monash University
RNA binding motif 5 is a lung tumour suppressor (2014-16)

Dr Peter Janes, Prof Dimitar Nikolov, Dr Elgene Lim
Monash University
Novel therapeutic antibodies to fight drug resistant breast cancers  (2016-18)

Dr Peter Janes, Prof Andrew Scott, A/Prof Thomas John
Monash University
Targeted antibody therapy for malignant mesothelioma 
Lyall Watts Mesothelioma Research Grant (Sept 2016 - Aug 2019)

A/Prof Brendan Jenkins, Prof Patrick Tan
Hudson Institute of Medical Research
Elucidation of the molecular basis by which the innate immune receptor TLR2 promotes gastric tumourigenesis (2014-16)

Dr Tom John, A/Prof Paul Mitchell, Dr Vinod Ganju, Prof Jonathan Cebon, Mr Simon Knight
Olivia Newton-John Cancer Research Institute
Melbourne Mesothelioma Research Collaborative
Mesothelioma Grant (2014-16)

Dr Gemma Kelly
The Walter and Eliza Hall Institute of Medical Research
Investigating the function of the EBV-encoded BCL-2 homologue, BHRF1 (2015-17)

A/Prof Michael Kershaw, A/Prof Phillip Darcy
Peter MacCallum Cancer Centre
Genetic redirection of immunity against cancer (2014-16)

Prof Finlay Macrae (VIC), A/Prof Alex Boussioutas (VIC), Dr Julie Clarke (SA), Dr David Topping (SA), Dr Shusuki Toden (SA), Prof Patrick Lynch (USA), Prof Allan Spigelman (NSW), Dr Mark Appleyard (QLD), Dr Paul Hollington (SA), Dr Hooi Ee (WA), Prof Don Cameron (VIC)
Melbourne Health
The effects of butyrylated high amylose maize starch on polyposis in FAP volunteers (2011-16)

Dr James Murphy, Dr Silvia Alvarez-Dias, A/Prof Matthias Ernst
The Walter and Eliza Hall Institute of Medical Research
The role of the essential necroptosis effector, MLKL, in gastrointestinal tumorigenesis (2015-17)

Prof Stephen Nutt, A/Prof Lynn Corcoran
The Walter and Eliza Hall Institute of Medical Research
Identification of new therapeutic targets in plasma cells and multiple myeloma  (2016-2018)

Prof Richard Pearson, Dr Katherine Hannan
The University of Melbourne
Targeting P13K/AKT-dependent cellular senescence to treat cancer (2014-16)

Prof Wayne Phillips (Sept 2015-Dec 2016), Dr Kathryn Kinross (Jan 2013-Sept 2015)
The University of Melbourne
Mechanisms of resistance to P13K pathway inhibitors in ovarian cancer (2013-16) 

Dr Gretchen Poortinga, Prof Grant McArthur, Prof Ross Hannan
Peter MacCallum Cancer Centre
Elucidating mechanisms of resistance to therapeutic inhibition of RNA polymerase 1 transcription (2016-18) 

A/Prof Louise Purton, Dr Meaghan Wall, Dr Carl Walkley
St Vincent's Institute of Medical Research
Impact of deregulated HOXA1 splicing in myelodysplastic syndromes (2016-18)

Dr Leonie Quinn, Dr David Levens
The University of Melbourne
Investigating roles for the FUBP family of Myc-regulators and their novel transcriptional targets in coordinating animal growth in vivo (2014-16)

Prof Jamie Rossjohn, Prof Andrew Brooks
Monash University
Exploring the role of human Natural Killer cells in tumour immunity (2016-18)

Dr Oliver Sieber, Prof Robyn Ward
Walter and Eliza Hall Institute of Medical Research
Identification of novel colon cancer genes predictive for prognosis and 5-fluorouracil therapy benefit (2014-16)

Dr Mark Shackleton, A/Prof Kieran Harvey
Peter MacCallum Cancer Centre
Melanoma and the Hippo pathway (2015-17)

Dr Karen Sheppard, Prof Grant McArthur
Peter MacCallum Cancer Centre
Acquired resistance to CDK4 inhibition in melanoma  (2016-18)

Dr Jake Shortt, Prof Ricky Johnstone
Peter MacCallum Cancer Centre
Overcoming resistance to bromodomain inhibition in MYC driven lymphoma (2015-17)

Prof Andreas Strasser, Dr Daniel Gray
Walter and Eliza Hall Institute of Medical Research
The mechanisms of cell competition that suppress cancer development (2016-18)

Prof Jose Villadangos, Prof William Heath
The University of Melbourne
Characterisation and prevention of "Stunning", a cytotoxic T lymphocyte inactivating program that impairs adoptive cell therapy against cancer (2016-18)

Dr Michaela Waibel, Prof Ricky Johnstone, Prof John Seymour
Peter MacCallum Cancer Centre
Rational combination therapies for JAK-driven haematological malignancies (2015-17)

Dr Florian Wiede
Monash University
PTPN2 and adoptive T cell immunotherapy (2016-18)

Updated: 25 Aug, 2016